Histiocytosis
MONDO:0002637A morphologic finding indicating tissue infiltration by non-neoplastic or neoplastic histiocytes.
Also known as: histiocytic infiltrate, histiocytic syndrome, histiocytic and dendritic cell neoplasms
75 clinical trials for this condition and its sub-types, 16 tagged with Histiocytosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Histiocytosis
-
Langerhans cell histiocytosis 40 trials · 41 incl. sub-types
8 sub-types
- Langerhans cell histiocytosis specific to childhood 1 trial Sub-types →
- Langerhans cell histiocytosis specific to adulthood 0 trials Sub-types →
- Eosinophilic granuloma 0 trials Sub-types →
- Hand-Schuller-Christian disease 0 trials
- Multisystem langerhans cell histiocytosis 0 trials
- Pulmonary langerhans cell histiocytosis 0 trials
- Single-system multifocal langerhans cell histiocytosis 0 trials
- Unifocal langerhans cell histiocytosis 0 trials
-
Non-Langerhans cell histiocytosis 1 trial · 39 incl. sub-types
15 sub-types
- Niemann-Pick disease 10 trials · 22 incl. sub-types Sub-types →
- Erdheim-Chester disease 14 trials
- Sinus histiocytosis with massive lymphadenopathy 11 trials Sub-types →
- Juvenile xanthogranuloma 4 trials
- Indeterminate dendritic cell tumor 1 trial
- Xanthogranuloma 1 trial Sub-types →
- Benign cephalic histiocytosis 0 trials
- Generalized eruptive histiocytosis 0 trials
- Hereditary progressive mucinous histiocytosis 0 trials
- Multicentric reticulohistiocytosis 0 trials
- Necrobiotic xanthogranuloma 0 trials
- Papular xanthoma 0 trials
- Progressive nodular histiocytosis 0 trials
- Sea-blue histiocyte syndrome 0 trials
- Xanthoma disseminatum 0 trials
-
Malignant histiocytosis 3 trials
-
ALK+ histiocytosis 0 trials
-
Reticulohistiocytic granuloma 0 trials
Most studied deeper sub-types
-
New pill shows promise for rare childhood diseases
Disease control Recruiting nowThis phase 2 trial is testing the drug mirdametinib in 40 people aged 2 and older with Langerhans cell histiocytosis or similar disorders. The goal is to see if this oral medication works better and has fewer side effects than current treatments. Participants take the drug twice …
Phase 2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Sep 21, 2026 22:00 UTC
-
New pill targets Hard-to-Treat cancers: early trial recruits 554 patients
Disease control Recruiting nowThis study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…
Phase 1/2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for kids with rare blood disorder: trametinib trial launches
Disease control Recruiting nowThis study tests the drug trametinib in children with histiocytosis, a rare blood disorder, that hasn't responded to standard treatments or has a specific genetic profile. The trial aims to find the best dose and timing to improve how long children live without their disease gett…
Phase 2 • Sponsor: Anna Raciborska • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for kids with rare blood cancer: targeted drug trial launches
Disease control Recruiting nowThis study tests the drug vemurafenib in children with a rare blood disorder called histiocytosis that has a specific gene mutation (BRAF) and hasn't improved with standard treatments. The goal is to find the best dose and how long to give the drug to stop the disease from gettin…
Phase 2 • Sponsor: Anna Raciborska • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New imaging test could spot rare childhood disease sooner
Diagnosis Recruiting nowThis study aims to improve how doctors diagnose and monitor histiocytosis, a rare disease that causes abnormal cell growth, in children under 18. Researchers will use a special imaging agent called fluorodeoxyglucose (18F-FDG) in PET-CT scans, along with genetic testing of tumor …
Phase 3 • Sponsor: Anna Raciborska • Aim: Diagnosis
Last updated Aug 23, 2026 00:00 UTC
-
500 patients needed to unlock secrets of rare histiocytic disorders
Knowledge-focused Recruiting nowThis study at Mayo Clinic will collect medical histories and blood, fluid, or tissue samples from 500 people with histiocytic disorders. Researchers will analyze these samples for molecular markers like BRAF V600E and PD-L1 to better understand the diseases. The goal is to gather…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Massive study tracks hidden toll of rare immune diseases
Knowledge-focused Recruiting nowThis study follows 6,000 people with histiocytic disorders (like Langerhans cell histiocytosis) to understand long-term health problems, pain, mental health, and causes of death. Researchers compare participants to healthy controls to identify factors that lead to new health issu…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC